Clovis Oncology (CLVS) Peer Comparison
$0.09
$0.00
(3.33%)
As on 22-Feb-2023 09:30EST
Market cap
$12 Mln
Revenue (TTM)
$133 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Edit
| Clovis Oncology (CLVS) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | Krystal Biotech (KRYS) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
12 | 16,932 | 14,858 | 9,943 | 9,835 |
Revenue ($ Mln) |
133 | 2,497 | 1,664 | 1,284 | 440 |
Net Profit ($ Mln) |
-251.91 | 885.14 | 413.60 | -325.10 | 241.47 |
Net Margin (%) |
-202.26 | 35.45 | 24.86 | -25.32 | 54.82 |
RoE (%) |
-- | 46.96 | 430.03 | -57.72 | 18.73 |
Price to Earnings |
-- | 20.78 | 38.28 | -- | 41.64 |
Price-To-Book |
-- | 9.23 | 103.48 | 19.04 | 7.24 |
Income Statement ($ Mln)
| Clovis Oncology (CLVS) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | Krystal Biotech (KRYS) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
133.02 | 1,434.97 | 443.31 | 0.00 | 0.00 |
|
Cost of Revenue
|
35.62 | 52.87 | 81.41 | 0.41 | 2.77 |
|
Gross Profit
|
109.93 | 1,382.10 | 361.90 | 0.00 | -2.77 |
|
Operating Expenses
|
297.62 | 1,095.43 | 86.00 | 242.48 | 68.28 |
|
Operating Profit (EBIT)
|
-230.88 | 286.67 | 275.90 | -242.48 | -68.28 |
|
Other Income
|
-8.48 | -0.18 | -19.86 | 0.36 | -- |
|
Profit before Tax
|
-252.31 | 294.15 | 248.52 | -241.85 | -69.57 |
|
Provision for Tax
|
-0.41 | 63.09 | -154.19 | -0.77 | 2.73 |
|
Profit after Tax (Net Income)
|
-251.91 | 231.06 | 402.71 | -241.08 | -69.57 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
-251.90 | 231.06 | 402.71 | -241.85 | -69.57 |
Liabilities ($ Mln)
| Clovis Oncology (CLVS) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | Krystal Biotech (KRYS) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-417.89 | 2,210.62 | 196.95 | 196.11 | 593.58 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
455.11 | 68.03 | 790.33 | 0.39 | 6.98 |
|
Current Liabilities
|
747.87 | 337.59 | 117.15 | 76.84 | 25.74 |
|
Total Liabilities
|
472.83 | 2,616.24 | 1,104.43 | 273.33 | 626.30 |
Assets ($ Mln)
| Clovis Oncology (CLVS) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | Krystal Biotech (KRYS) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
244.57 | 781.49 | 178.14 | 1.65 | 184.03 |
|
Current Assets
|
102.21 | 1,834.75 | 926.29 | 271.68 | 442.27 |
|
Total Assets
|
472.83 | 2,616.24 | 1,104.43 | 273.33 | 626.30 |
|
Total Debt*
|
458.57 | 51.27 | 876.67 | 0.80 | 8.02 |
|
Net Current Assets
|
-645.66 | 1,497.16 | 809.14 | 194.85 | 416.53 |
Cashflow ($ Mln)
| Clovis Oncology (CLVS) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | Krystal Biotech (KRYS) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-196.06 | 400.80 | 299.44 | -183.92 | -47.94 |
|
Cash Flow from Investing Activities
|
-0.31 | -42.88 | -406.29 | -5.06 | -226.77 |
|
Cash from Financing Activities
|
100.16 | -14.80 | 77.87 | 171.24 | 347.69 |
|
Net Cash Inflow / Outflow
|
-96.21 | 52.64 | -28.98 | -17.74 | 72.98 |
Ratios
Profitability Ratios
| Clovis Oncology (CLVS) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | Krystal Biotech (KRYS) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-62.41 | 11.03 | 49.66 | -110.17 | -15.37 |
|
ROE (%)
|
120.90 | 11.30 | 231.44 | -110.57 | -15.71 |
|
ROA (%)
|
-29.37 | 9.72 | 47.82 | -86.05 | -14.85 |
|
EBIT Margin (%)
|
-163.01 | -- | -- | -- | -- |
|
Net Margin (%)
|
-202.26 | 16.10 | 95.10 | -66,412.67 | -- |
|
Cash Profit Margin (%)
|
0.00 | -- | -- | -- | -- |
Growth Ratios
| Clovis Oncology (CLVS) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | Krystal Biotech (KRYS) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-14.78 | 0.45 | 0.66 | -- | -- |
|
EBIT Growth (%)
|
19.45 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
15.78 | 106.71 | 211.97 | -22.10 | -116.28 |
|
EPS Growth (%)
|
-- | 1.04 | 2.14 | -0.11 | -0.95 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Clovis Oncology (CLVS) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | Krystal Biotech (KRYS) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | 25.57 | 14.40 | -6.00 | -22.33 |
|
Price / Book Value
|
-- | 2.67 | 29.45 | 7.38 | 2.62 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-2.20 | 14.96 | 21.28 | -4.86 | -17.20 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Clovis Oncology (CLVS) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | Krystal Biotech (KRYS) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.02 | 4.45 | 0.00 | 0.01 |
|
Short term debt to equity ratio
|
-0.01 | 0.00 | 0.45 | 0.00 | 0.00 |
|
Current Ratio
|
0.14 | 5.43 | 7.91 | 3.54 | 17.18 |
|
Quick Ratio
|
0.12 | 5.35 | 7.45 | -- | -- |
|
Interest Coverage
|
-6.11 | -- | 36.66 | -232.93 | -45.63 |
Operating Efficiency Ratios
| Clovis Oncology (CLVS) | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | Madrigal Pharmaceuticals (MDGL) | Krystal Biotech (KRYS) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
14.62 | 19.70 | 20.52 | -- | -- |
|
Asset Turnover
|
0.16 | 0.60 | 0.53 | 0.00 | 0.00 |
|
Receivable days
|
78.90 | 56.45 | 77.74 | -- | -- |
|
Inventory Days
|
208.85 | 167.40 | 257.19 | -- | -- |
|
Payable days
|
254.00 | 165.41 | 7.78 | 10,099.39 | 692.71 |
|
Cash Conversion Cycle
|
33.76 | 58.44 | 327.15 | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
